Pablo Pérez López

Thrilled to begin my new role as SoMe editor at #EHJCVI! Excited to help share the latest advancements in cardiovascular imaging research! Grateful to @EHJCVIEiC, @JGrapsa, and @EZancanaroMD for the trust and opportunity!

The World Youth Heart Federation (@WYHFGlobal) is now officially accepting applications for National Chapters! Join us for an info session on May 9 at 7 PM (EST). Learn how creating a #WYHF National Chapter allows you to: ✅ Join a growing global network of youth leaders ✅ Lead and contribute to youth-driven cardiovascular health campaigns ✅ And more! Info Session Registration: bit.ly/4n3iMWu Application (Deadline May 31): bit.ly/49fd2mz

#EHJCVI 🫀 LA strain by #whyCMR refines risk stratification in #HCM with low SCD risk 💡 LVEF>50% + LGE<5% + LA-GLS>37.6% identified an ultra-low-risk subgroup with MACE rate of just 2% ‼️ ⏩ Read more: doi.org/10.1093/ehjci/…

#EHJCVI 🫀 🔍 Should stage 3-4 cardiac damage flag futility in #TAVI? In the COMPARE-TAVI 1 sub-study (n=985), all CD stages benefited from TAVI, with similar 1-year futility (death/NYHA 3-4) across groups ‼️ #echofirst #VHD ⏩ Read more: doi.org/10.1093/ehjci/…

Few people have shaped cardiovascular medicine so profoundly or for so long as Dr. Eugene Braunwald. For generations of discovery, his contributions helped define modern cardiology and strengthened the foundation on which today’s breakthroughs stand. His legacy lives on not only in these medical discoveries, but in the people he inspired and mentored, including many leaders who continue to shape cardiovascular care today.

The American Heart Association mourns the passing of the legendary cardiologist Eugene Braunwald, M.D., widely recognized as one of the most influential figures in the history of cardiovascular medicine. Over seven decades, his work reshaped the understanding and treatment of heart disease, leading many to call him the father of modern cardiology. Braunwald was a lifelong contributor to the American Heart Association, helping advance its research and scientific mission, and was honored with some of the Association’s highest honors for his lasting influence on cardiovascular care and research. His influence extended well beyond his own discoveries, as generations of Association‑supported investigators, clinicians and academic leaders were trained by Braunwald or guided by the clinical trial standards and mentorship models he helped establish. newsroom.heart.org/news/american-…

news.med.miami.edu/pilar-alcaide-… @umiamimedicine @univmiami @SylvesterCancer

VALVE-iPROTECT is an initiative led by @AikawaElena bridging basic science, clinical imaging, and population studies to revolutionize aortic stenosis detection and treatment, made possible by @American_Heart. Read more here: newsroom.heart.org/news/scientifi…

Great to have Javid Moslehi @CardioOncology at @YaleCardiology Grand Rounds. A great discussion on a translational research journey. From bedside to bench and back. ICI myocarditis as a great example. @ericjvelazquez @KatAAClark @hattaca

#EHJCVI 📊🧠 In CCTA, risk evolves over time. Stenosis severity predicts short-term events, while plaque burden (PAV) drives long-term outcomes, highlighting the dynamic nature of CAD risk #YesCCT 🔗 Read more -> doi.org/10.1093/ehjci/…

#EHJCVI 🧲 LGE phenotype drives risk in NICM. Septal mid-wall + lateral subendocardial patterns predict SCD, highest when combined, outperforming LVEF 🔎 #WhyCMR Read more -> 🔗 doi.org/10.1093/ehjci/…

#EHJCVI ⚠️ CMR staging after STEMI matters 📈 Higher CCS stages of myocardial injury predict worse 1-year outcomes, stage 4 carries the highest risk of MACE and mortality. #WhyCMR 🔗 doi.org/10.1093/ehjci/…

#EHJCVI 🧲📊 DANAMI-3: ↓ infarct size/transmurality and ↑ myocardial salvage index/LVEF (at acute + 3 months) were associated with lower 10-year mortality/HF hospitalization, while microvascular obstruction was not #WhyCMR 🔗 Read more -> doi.org/10.1093/ehjci/…

Check out this study investigating the effects of Colchicine on Coronary Plaque Progression. One of my highlight picks recently published in #EHJCVI #yesCCT @BudoffMd

#EHJCVI 📊 EKSTROM trial: at 1 year, colchicine 0.5 mg/day did not reduce low-attenuation plaque, but slowed progression of total plaque burden on CCTA, highlighting a potential role in modulating plaque progression #yesCCT 🔗 Read more -> doi.org/10.1093/ehjci/…

🔔 Save the date! Join us for the III Cardioimmunology Congress 2026, exploring the latest breakthroughs redefining the understanding of #CardiacDisease through the lens of #Immunology. Hosted by @CNIC_CARDIO and @umiamimedicine. 🗓 Sept 30 – Oct 2, 2026 📍 Real Sitio de San Ildefonso, La Granja (Segovia), Spain 🚀 Registration and abstract submission are now open! 👉 cardioimmunology2026.com #CNIC #CardiovascularResearch #Cardioimmunology

#EHJCVI 🧲 MRI reveals what wall thickness alone can miss 📏 Wall Thickness SD (WTSD) identifies both overt and early hypertrophic cardiomyopathy, even before hypertrophy is evident 🔍✨Read more 👉 doi.org/10.1093/ehjci/…

#Cardioimmunology2026 🇪🇸 in the making with @PilarMartinFern Don't miss out and register for the meeting now👇#cardiovascularhealth #immunoloy cardioimmunology2026.com

@BenekiEirini @MSBBrandao @ErsozluSara @AdrianaCMares @CristinaRomanMD @echo_stepbystep @pabloplopez_ @JGrapsa #EHJCVI 🫀QUIZ‼️ Answer: Pheochromocytoma-induced MINOCA (Ku et al., doi.org/10.1093/ehjci/…) 🧠 A rare but reversible cause. Early recognition is key.

#EHJCVI🫀QUIZ‼️A 14-year-old presents with chest pain, elevated troponin, LV dysfunction, and normal coronaries on CTA. MRI shows myocardial injury and an incidental adrenal mass❓ What is the most likely underlying cause?

Honored to be selected as one of 6 new leaders for the @ACCinTouch Medical Student Leadership Group (MSLG). Grateful for the opportunity to contribute to the future of cardiology, amplify student voices, and grow alongside incredible peers and mentors. Let’s build something meaningful. 🫀 #ACCMedStudent #CardioTwitter #ACCLeadership #ACCEarlyCareers #MedicalStudent